New vaccine aims to fight deadly brain cancer

NCT ID NCT06622434

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a cancer vaccine for people with newly diagnosed glioblastoma, a serious brain cancer. The vaccine is designed to help the immune system attack tumor cells. About 35 participants will receive the vaccine after standard treatment. The goal is to see if it is safe and boosts the immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cancer vaccine targeting TERT and PTPRZ1 proteins
What this could lead to: If successful, this could lead to a new treatment option that helps control glioblastoma and extends survival.
What could go wrong: This is an early-phase trial with only 35 participants, so results may not apply to all patients. The vaccine may not trigger a strong enough immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEWLY DIAGNOSED GLIOBLASTOMA

Contacts and locations

Locations

Department of Neurology, Hopital Saint louis (APHP)
RECRUITING

Paris, 75010, France
Department of Neurology, Hopital de la Salpêtrière
RECRUITING

Paris, Idf, 75013, France
Neuro-oncology Department, La Timone Hospital
NOT_YET_RECRUITING

Marseille, Provence-Alpes-Côte d'Azur Region, 13005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.